Sandoz (SIX:SDZ / OTCQX:SDZNY), the global leader in affordable medicines, will host its 2026 capital markets day for investors and analysts on Tuesday, 8 September, at the London Stock Exchange. The event, which runs from 13:30 to 17:00 UK time, will be available via live webcast, with in-person attendance by invitation only on a first-come, first-served basis. Details of how to access the live webcast are available here.
The capital markets day comes as Sandoz celebrates 20 years of pioneering biosimilars in 2026, a milestone the company describes as its 'golden decade' for biosimilars. The event is expected to provide strategic insights into how Sandoz plans to maximise value in this rapidly growing market. Biosimilars, which are nearly identical copies of biologic drugs, offer significant cost savings to healthcare systems and expand patient access to advanced therapies. Sandoz's leadership in this space is underscored by its extensive portfolio and global reach.
In addition to the capital markets day, Sandoz plans to host an investor and analyst site visit in Slovenia from 9-10 November. This visit will provide further insight into the Company’s new biosimilars development and supply-chain hub. Attendance will again be by invitation only on a first-come, first-served basis, and the event will not be webcasted. The Slovenia hub represents a key investment in Sandoz's biosimilars capabilities, enhancing its ability to develop and manufacture these complex medicines efficiently.
Sandoz's focus on biosimilars is part of a broader growth strategy driven by its purpose: pioneering access for patients. With more than 20,000 colleagues of 100 nationalities, the company reaches over one billion patients, generating substantial global healthcare savings. Its leading portfolio of approximately 1,300 medicines addresses diseases from the common cold to cancer. In 2025, Sandoz recorded net sales of USD 11.1 billion.
The capital markets day and site visit underscore Sandoz's commitment to transparency with the investment community, providing a deep dive into its strategic priorities and operational strengths. As the biosimilars market continues to expand, driven by patent expiries of major biologics and increasing demand for affordable treatments, Sandoz is well-positioned to capture growth opportunities. The events will likely cover topics such as pipeline updates, manufacturing efficiencies, and market access strategies.
Forward-looking statements in the announcement caution that actual outcomes may vary materially due to risks including global economic conditions, exchange rates, legal provisions, market conditions, and competitive activities. Sandoz undertakes no obligation to publicly revise any forward-looking statements, except as required by law.
For more information about the company and its events, visit the Sandoz website at www.sandoz.com.
